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The major aim of this study is to develop the new class of coumarin candidate clubbed with dihydropyridine-3-
carbonitrile with an improved potency as an antimicrobial and antioxidant agent. The key intermediate 6-nitro-4-methyl 
coumarin-yl chloro acetate 5 have been linked to the 6-(4-fluorophenyl)-2-oxo-4-phenyl-1,2-dihydro pyridine-3-carbonitrile 
IIa-j derivative to afford 4-methyl-6-nitro-2-oxo-2H-chromen-7-yl-2-(3-cyano-6-(4-fluoro phenyl)-4-(substituted-phenyl) 
pyridin-2-yl-oxy) acetates 7a-j via efficient organic transformations. All the new derivatives have been characterized by 
spectral studies (IR, 1H and 13C NMR and mass spectroscopy). In vitro antimicrobial activity have been carried out using the 
broth microdilution method and antioxidant potency using DPPH bioassays. Bioassay results reveal that compound 7e are 
equipotent against E. coli with MIC value 50 µg/ mL compared to standard drug ciprofoloxacin. A final analogue 7c with 4-
chlorophenyl substituent indicated better antifungal potency against C. albicans with MIC value 100 µg/ mL compared to 
standard drug griseofulvin. In addition, newly synthesized analogues have been found to be significant scavengers of DPPH 
radical with IC50 values of 32.11 µg/mL. It has been observed that the potent antibacterial candidate has proved to possess 
significant antioxidant activity. The presence of chlorine and hydroxy group on phenyl ring plays an important role for the 
potency in above mentioned biological assay. 
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The increasing resistance of pathogenic 
microorganisms to conventional drugs has become a 
serious problem in healthcare. This requires the 
urgent need to replace existing therapeutics with 
better alternatives. Heterocyclic hybridization 
approach to design new bioactive molecule is an 
emerging tool in drug discovery because it allows 
integrating two or more pharmacophore into one 
molecular scaffold with an improved pharmacological 
activities. Among a large variety of heterocyclic 
compounds, coumarin, a condensed heterocycle of 
benzene and pyran-2-one, recognized as an important 
pharmacophore. It is widely reported that natural1 and 
synthetic coumarin2 analogous shows a significant 
pharmacological effect. Novobiocin and Chlorobiocin 
are well known antimicrobials containing a coumarin 
nucleus3. Presence of coumarin nucleus in numerous 
categories of therapeutic agents such as antibacterial4, 
antifungal5, antitubercular6, antiviral7, antimalarial8, 
analgesic9, antiparasitic10, antitumor11, anti-
inflammatory12, antioxidants13, anticoagulants14, 
antidiabetics15, etc. has made it a valuable lead for the 
development of new therapeutic agents. Antimicrobial 
activity of nitro coumarins has been reviewed 
extensively16,17 and it has been observed that when the 
nitro group has been incorporated with coumarin, its 
antimicrobial activities is enhanced. The derivatives 
contain pyridine core are versatile and used as active 
pharmaceutical ingredients18. Among the varied 
pyridine derivatives, 3-cyanopyridines comprise a 
very interesting class of compounds because of their 
significant and versatile biological activities19,20, viz, 
neurotropic activity21, anti-inflammatory, analgesic22, 
antioxidant23, Tyrosine kinase inhibitors24, etc. 
With this consideration and continuation25 of our 
ongoing interest in the synthesis of the pyridine 
clubbed coumarin derivatives, we have been 
prompted to synthesize possibly more potent 
pharmacologically active compounds. The present 
article deals with the design and synthesis of 
coumarin clubbed pyridine-3-carbonitrile analogous. 
We have condensed chloro acetate of 4-methyl-7-




hydroxy -6- nitrocoumarin with hydoxy pyridine 
intermediates. The synthesized compounds were 
assigned on the basis of IR, 1H NMR, 13C NMR and 
mass spectral data. The in vitro antimicrobial 
evaluation of these derivatives were obtained by broth 
microdilution method and antioxidant activity have 
been evaluated by 2,2’-diphenyl-1-picrylhydrazyl 
(DPPH) radical scavenging assay. 
 
Results and Discussion 
Chemistry 
Scheme I represents the synthetic pathway 
followed to generate key intermediates (5) and IIa-j 
along with the final coumarine clubbed pyridine 
derivatives (7a–j). According to Scheme I, synthesis 
of 4-methyl-7-hydroxy-coumarin (3) by Pechmann 
condensation followed by nitration with cerric 
ammonium nitrate and then reacting with chloroacetyl 
chloride yielding 4-methyl-3-nitro-2-oxo-2H-
chromen-7-yl 2-chloroacetate (5). For the synthesis of 
final compounds (Figure 1), the key intermediate (5) 
was condensed with 6-(4-fluorophenyl)-2-oxo-4-
substituted-phenyl-1,2-dihydropyridine-3-
carbonitriles (IIa-j) which are obtained via the 
multicomponent reaction using 4-fluoroacetophenone, 
substituted benzaldehyde and ethylcyanoacetate in the 
presence of ammonium acetate in ethanol. The 
structure of key intermediates and compounds 7a-j 
were characterized and confirmed utilizing 
spectroscopic techniques such as IR, 1H and 13C NMR 
and mass spectrometry. Absorption bands at 3037, 
2912 cm−1 for the IR of 7a-j confirmed the presence 
of C-H stretching for aromatics and -CH3 group, 
whereas C-N banding observed at 2226 cm−1. The 
>C=O band indicated a sharp peak nearby 1714 and 
1687 cm−1 along with sharp >C=N- stretching at 1624 
cm−1. The various characteristic bands nearer to 1161 
for aryl-F and 1510, 1347 indicate the presence of  
-NO2 group in the final compounds. 
1H NMR 
spectrum of compound showed singlet at 8.58 for 
 –CH confirmed the neighboring -NO2 group while  





Figure 1 — Numbering of carbon atoms in the representative 
structure of the final compound (4-methyl-6-nitro-2-oxo-2H-
chromen-7-yl 2-((3-cyano-6-(4-fluorophenyl)-4-phenylpyridin-2-
yl)oxy)acetate) 




respectively. The 13C NMR data observed for 
compounds 7a-j further confirmed the correct 
formation of the synthesized structure. 13C NMR 
spectrum showed peaks at 160.63 and 165.06 for two 
different C=O, one peak at 19.40 for -CH3 of coumarin, 
114.21 was obtained for –C≡N group, which confirming 
the structure of final compounds. The high-resolution 
mass spectral data of the final derivatives exhibited 
molecular ion peaks at their respective molecular 




Antibacterial and antifungal activities of 7a-j were 
evaluated (Table I). Among all the synthesized 
compounds, 7e showed better antibacterial activity 
against E. coli and 7c demonstrates the best antifungal 
activity against C. albicans. All the other compounds 
had moderate to poor activity as antifungal agents 
with higher MIC values. Both electron withdrawing 
and donating groups at ortho-, meta-, and para- 
position on the phenyl ring of 6-(4-fluorophenyl)-2-
hydroxy-4-phenylnicotinonitrile were introduced to 
explore the SAR. From the wet lab results of the final 
derivatives, it can be observed that most compounds 
exhibited relatively moderate antibacterial activities. 
4-Cl and 4-OH derivatives displayed better activity as 
antibacterial agent. This observation suggests that, the 
substitution position on the phenyl ring attached to the 
3-cyno pyridine appeared to have influence on the 
antibacterial activity. The compound 7c with 4-Cl 
substituted showed the same antibacterial potency 
against S. aureus, S. payogens and E. coli with MIC 
value 62.5 µg/mL, whereas the change the position of 
same substituent showed poor antimicrobial potency. 
The compound 7c found to be equipotent antifungal 
agent (MIC = 100 µg/mL) compared to standard drug 
nystatin. Introduction of electron donation –OH group 
on same phenyl ring on para position decrease the 
antifungal potency but enhanced the antibacterial 
activity against E. coli. with MIC value 50 µg/mL 
when compared with ciprofloxacin. The position of –
OH group on phenyl ring plays an important role. 
Other compounds had very high MIC values and 
seem to be poor to moderately active. 
 
Antioxidant evaluation 
The antioxidant activity by DPPH radical 
scavenging from ten coumarin derivatives is showed 
in Table II. 3-Cynopyridine moiety was incorporated 
to our compounds with different substituent on one of 
the aromatic ring. The compound 7c which was found 
to be better antimicrobial showed a null activity. 
Interestingly, incorporation from hydoxy substituent 
at 4-position on the aromatic ring drastically enhance 
the biological activity (compound 7e, IC50  
32.11 µg/mL), although incorporation same 
substituent on 2-position not affect the biological 
activity (compound 7d, IC50 66.20 µg/mL). 
Interestingly, a change in the position of hydoxy atom 
in the phenyl ring of compound 7d to obtain 
compounds 7e has positive antioxidant potency. 
Table I — Antibacterial and Antifungal activity of compounds 7a-j 
Compd MIC (µg/mL) 




















7a 100 100 100 200 500 500 500 
7b 250 250 250 125 500 1000 1000 
7c 62.5 62.5 62.5 100 100 500 500 
7d 125 200 100 250 1000 500 1000 
7e 62.5 100 50 100 250 1000 1000 
7f 250 100 125 250 500 1000 >1000 
7g 125 250 250 250 1000 500 1000 
7h 62.5 200 62.5 125 500 1000 500 
7i 250 200 100 100 500 1000 1000 
7j 200 100 200 200 >1000 >1000 >1000 
Ciprofloxacin 25 25 50 50 − − − 
Nystatin − − − − 100 100 100 




These results suggest explore more substituent on that 
aromatic ring to obtain a better structure-activity 
relationship. Introduction of methyl group at 4-
position showed better result compared to other 
derivatives (compound 7e). These results can be 
comparable to that of control ascorbic acid while 
other compounds have very poor antioxidant power. 
 
Experimental Section 
The starting materials were purchased from Sigma-
Aldrich with the highest purity and used without 
further purification. Analytical thin layer 
chromatography (TLC) was performed with Merck 
silica gel plates and visualized with UV irradiation 
(254 nm) or iodine. Melting points were determined 
with open capillary method on ‘Equiptronics’ digital 
melting point apparatus, model no. EQ-730 and were 
uncorrected. IR spectra were recorded on a Perkin 
Elmer spectrophotometer (KBr pellets) instrument. 
1H NMR and 13C NMR spectra were recorded on 
Bruker Avance II 400MHz and 100MHz respectively 
NMR spectrometer using DMSO-d6 as solvent and 
TMS as internal standard. All chemical shifts were 
reported as δ values (ppm). Mass spectra were 
recorded using Expression CMS from Advion, USA 
using ESI as ion source (mobile phase 0.1% Formic 




4-Methyl -7-hydroxy-coumarin 3 has been 
prepared as described in the literature26: White solid. 
Yield: 85%. m.p.183°C to 185°C. IR (KBr): 3493(-
OH), 3098, 2817 (-CH3, asym, sym), 1735 (>C=O 
str), 1148 cm−1 (-C-O-C); 1H NMR (DMSO-d6) δ 
(ppm): 10.35 (s, 1H, Phenolic -OH), 7.48 (d, 1H, 
aromatic) 6.76 (d,1H,aromatic), 6.69 (s, 1H,aromatic), 




has been prepared as described in the literature27. 
Yellow solid. Yield: 72%. m.p.193-195°C (as 
reported). IR (KBr): 3490 (-OH), 3094, 2827 (-CH3, 
asym, sym), 1745 (>C=O str), 1190 (-C-O-C), 1536, 
1357 cm−1 (-NO2); 
1H NMR (DMSO-d6) δ 
(ppm):13.26 (s, 1H, Phenolic -OH), 8.44 (s, 1H, 
aromatic), 7.09 (s, 1H, aromatic), 6.35 (s, 1H, 





acetate 5 has been prepared as described in the 
literature28. Brownish yellow crystals. Yield: 69%, 
m.p.109°C - 112°C. IR (KBr): 3003, 2799 (-CH3, 
asym, sym), 1751, 1657 (>C=O str), 1190 (-C-O-C), 
1571, 1346 (-NO2), 831 cm
−1 (-C-Cl); 1H NMR 
(DMSO-d6): δ 8.38 (s, 1H, aromatic), 7.27 (s, 1H, 
aromatic), 6.37 (s, 1H, aromatic), 4.47 (s, 2H, -
COCH2), 2.48 (s, 3H, -CH3). 
 
General method for the synthesis of 6-(4-
fluorophenyl)-2-oxo-4-phenyl-1,2-dihydropyridine-
3-carbonitrile, IIa-j 
4-Fluoroacetophenone 6 (0.01 mol) and 
benzaldehyde (0.01 mol) were mixed in ethanol and 
stirred for 15 minutes, then ethylcyanoacetate (0.01 
mol) was added drop wise followed by the addition of 
ammonium acetate (0.08 mol) in 40mL ethanol. The 
reaction mixture was refluxed in a round bottom flask 
for 6-7 h. The reaction mass was cooled and poured 
on to crushed ice water, the obtained precipitates were 
filtered off, dried and the desired compound IIa 
recrystallized by ethyl alcohol. Yield: 65%, m.p.: 246-
248°C. IR (KBr): Compound IIg: 3330 (-OH), 2232 
(-CN), 1608 cm−1 (C=N); 1H NMR (400 MHz, 
DMSO-d6, TMS): δ 12.91 (s, 1H, -OH), 7.24-8.25 (m, 
9H, aromatic), 2.38 (s, 3H, -CH3). The other 
compounds IIb-j was prepared by the same method 
using various substituted benzaldehydes. 
 
General method for the synthesis of 4-methyl-6-
nitro-2-oxo-2H-chromen-7-yl-2-(3-cyano-6-(4-
fluoro phenyl)-4-(phenyl)pyridin-2-yl-oxy) acetate, 
7a-j 
To a solution of 4-methyl-6-nitro-2-oxo-2H-
chromen-7-yl-2-chloroacetate 5 (0.01 mol) and 6-(4-
Table II — Screening results of DPPH radical scavenging  
activity of 7a–j 
Compd IC50 µg/mL ± SD 
7a 52.97 ± 0.673 
7b 49.57 ± 0.487 
7c 79.12 ± 1.912 
7d 66.20 ± 0.995 
7e 32.11 ± 0.123 
7f 81.02 ± 1.438 
7g 37.08 ± 0.308 
7h 54.63 ± 0.812 
7i 41.67 ± 0.287 
7j 49.32 ± 0.451 
Ascorbic Acid 36.22 ± 0.469 
 





carbonitrile IIa (0.01 mol) in DMF, K2CO3 (0.24 mol) 
were added under stirring and were refluxed for 8-9 h. 
After the completion of the reaction (TLC monitored 
by using ethylacetate : n-hexane; 1:1), the mixture 
was poured on to crush ice, solids that are separated 
out was filtered, washed with saturated solution of 
NaHCO3 and recrystallized from ethanol. Yield: 61%, 
m.p.: 182-184°C. The other compounds 7b-j were 




yl)oxy) acetate 7a: Pale yellow solid. Yield: 78%, 
m.p.: 182-184°C, Mol. formula C30H18FN3O7. IR 
(KBr): 3037, 2912 (-CH3), 2227 (-CN) 1714, 1687 (-
C=O), 1624 (C=N), 1161 (aryl-F), 1510, 1347 cm−1 (-
NO2); 
1H NMR (400 MHz, DMSO-d6, TMS): δ 8.58 
(s, 1H, -CH), 6.37-8.24 (m, 12H, aromatic), 5.18 (s, 
2H, -CH2O), 2.40 (s, 3H, -CH3); 
13C NMR (100MHz, 
DMSO-d6 TMS): δ 160.63 (C-2),112.29 (C-3), 152.41 
(C-4), 120.58 (C-5), 137.42 (C-6), 135.58 (C-7), 
115.80 (C-8), 159.71 (C-9), 117.50 (C-10), 19.40 (C-
12), 191.75 (C-14), 68.90 (C-16), 165.06 (C-18), 
92.10 (C-19), 156.06 (C-20), 108.51 (C-21), 157.23 
(C-22), 140.02 (C-24), 126.78 (C-25, C-29), 130.15 
(C-26, C-28, C-27), 133.62 (C-31), 130.62 (C-32, C-
36), 116.05 (C-33, C-35), 161.52 (C-34), 114.21 (C-




pyridine-2-yl)oxy) acetate, 7b: Yellow solid. Yield: 
69%, m.p.: 178-180°C, Mol. formula C30H17ClFN3O7. 
IR (KBr): 3045, 2924 (-CH3), 2225 (-CN), 1723, 1679 
(-C=O), 1631 (C=N), 1159 (aryl-F), 1509, 1339 (-
NO2), 765 cm
−1 (C-Cl); 1H NMR (400 MHz, DMSO-
d6, TMS): δ 8.54 (s, 1H, -CH), 6.32-8.24 (m, 12H, 
aromatic), 5.09 (s, 2H, -CH2O), 2.41 (s, 3H, -CH3); 
13C NMR (100MHz, DMSO-d6 TMS): δ 160.63  
(C-2),112.29 (C-3), 152.41 (C-4), 120.58 (C-5), 
137.42 (C-6), 135.58 (C-7), 115.80 (C-8), 159.71 (C-
9), 117.50 (C-10), 19.40 (C-12), 192.75 (C-14), 68.79 
(C-16), 164.81 (C-18),93.10 (C-19), 156.06 (C-20), 
108.51 (C-21), 157.23 (C-22), 133.02 (C-24), 132.65 
(C-25), 132.15 (C-26), 128.69 (C-27),130.54 ( C-28 ), 
129.45 (C-29), 134.62 (C-31), 130.62 (C-32, C-36), 
116.05 (C-33, C-35), 163.52 (C-34), 113.89 (C-38), 




pyridine-2-yl)oxy) acetate, 7c: Yellow solid. Yield: 
76%, m.p.: 210-212°C, Mol. formula C30H17ClFN3O7. 
IR (KBr): 3052, 2934 (-CH3), 2224 (-CN), 1731, 1677 
(-C=O), 1629 (C=N), 1147 (aryl-F), 1511, 1345 (-
NO2), 771 cm
−1 (C-Cl); 1H NMR (400 MHz, DMSO-
d6, TMS): δ 8.54 (s, 1H, -CH), 6.32-8.24 (m, 12H, 
aromatic), 5.09 (s, 2H, -CH2O), 2.36 (s, 3H, -CH3); 
13C NMR (100MHz, DMSO-d6 TMS): 160.63  
(C-2),112.29 (C-3), 152.41 (C-4), 120.58 (C-5), 
137.42 (C-6), 135.58 (C-7), 115.80 (C-8), 159.71  
(C-9), 117.50 (C-10), 19.40 (C-12), 192.75 (C-14), 
68.79 (C-16), 164.81 (C-18),93.10 (C-19), 156.06 (C-
20), 108.51 (C-21), 157.23 (C-22), 133.02 (C-24), 
129.65 (C-25), 132.15 (C-26), 132.69 (C-27),130.54  
( C-28 ), 129.45 (C-29), 134.62 (C-31), 130.62 (C-32, 
C-36), 116.05 (C-33, C-35), 163.52 (C-34) 114.3  




pyridin-2-yl)oxy) acetate, 7d: Yellow solid. Yield: 
73%, m.p.: 156-158°C, Mol. formula C30H18FN3O8. 
IR (KBr): 3487(-OH), 3051, 2922 (-CH3), 2216  
(-CN), 1718, 1678 (-C=O), 1622 (C=N) 1521, 1350  
(-NO2), 1174 cm
−1 (C-F); 1H NMR (400 MHz, 
DMSO-d6, TMS): δ 9.41 (s, 1H, -OH), 8.59 (s, 1H, -
CH), 6.32-8.29 (m, 11H, aromatic), 5.18 (s, 2H, -
CH2O), 2.39 (s, 3H, -CH3);
 13C NMR (100MHz, 
DMSO-d6 TMS): δ 160.63 (C-2),112.22 (C-3), 152.48 
(C-4), 120.61 (C-5), 137.54 (C-6), 135.62 (C-7), 
115.88 (C-8), 159.75 (C-9), 117.57 (C-10), 19.45  
(C-12), 191.71 (C-14), 68.90 (C-16), 165.17  
(C-18),79.14 (C-19), 156.13 (C-20), 108.56 (C-21), 
157.24 (C-22), 128.25 (C-24), 130.57 (C-25),  
121.82 (C-26), 131.32 (C-27), 117.48 (C-28), 155.63 
(C-29), 133.60 (C-31), 130.59 (C-32, C-36), 116.14 





pyri din-2-yl)oxy) acetate, 7e: Light yellow solid. 
Yield: 81%, m.p.: 169-171°C, Mol. formula 
C30H18N3FO8. IR (KBr): 3481(-OH), 3057, 2925 (-
CH3), 2219 (-CN), 1716, 1679 (-C=O), 1624 (C=N) 
1516, 1348 (-NO2), 1175 cm
−1 (C-F); 1H NMR (400 
MHz, DMSO-d6, TMS): δ 10.26 (s, 1H, -OH), 8.59 (s, 
1H, -CH), 6.39-8.25 (m, 11H, aromatic), 5.19 (s, 2H, -
CH2O), 2.40 (s, 3H, -CH3);
 13C NMR (100MHz, 
DMSO-d6 TMS): δ 160.60 (C-2),112.27 (C-3), 152.51 
(C-4), 120.65 (C-5), 137.50 (C-6), 135.64 (C-7), 
115.85 (C-8), 159.79 (C-9), 117.54 (C-10), 19.41 (C-




12), 191.78 (C-14), 68.92 (C-16), 165.11 (C-
18),79.15 (C-19), 156.13 (C-20), 108.52 (C-21), 
157.27 (C-22), 131.56 (C-24), 130.08 (C-25, C-29), 
116.5 (C-26, C-28), 159.02 (C-27), 133.62 (C-31), 
130.62 (C-32, C-36), 116.05 (C-33, C-35), 161.52 (C-




yl)oxy) acetate, 7f: Yellow solid. Yield: 86%, m.p.: 
223-225°C, Mol. formula C31H17F2N3O7. IR (KBr): 
3029, 2933 (-CH3), 2225 (-CN) 1723, 1678 (-C=O), 
1645 (C=N), 1159 (aryl-F), 1504, 1351 cm−1 (-NO2); 
1H NMR (400 MHz, DMSO-d6, TMS): δ 8.49 (s, 1H, 
-CH), 6.36-8.23 (m, 11H, aromatic), 4.95 (s, 2H, -
CH2O), 2.41 (s, 3H, -CH3); 
13C NMR (100MHz, 
DMSO-d6 TMS): δ 160.51 (C-2),112.19 (C-3), 152.48 
(C-4), 120.64 (C-5), 137.48 (C-6), 135.67 (C-7), 
115.90 (C-8), 159.69 (C-9), 117.48 (C-10), 19.38 (C-
12), 191.68 (C-14), 69.03 (C-16), 165.20 (C-
18),79.09 (C-19), 156.13 (C-20), 108.54 (C-21), 
157.22 (C-22), 136.50 (C-24), 126.27 (C-25, C-29), 
129.91 (C-26, C-28), 162.12 (C-27), 133.54 (C-32, C-
34), 163.59 (C-33, C-37), 116.10 (C-34, C-36), 




yl)oxy) acetate, 7g: Yellow solid. Yield: 81%, m.p.: 
201-204°C, Mol. formula C31H20FN3O7. IR (KBr): 
3034, 2928 (-CH3), 2220 (-CN) 1714, 1687 (-C=O), 
1624 (C=N), 1161 (aryl-F), 1510, 1347 cm−1 (-NO2); 
1H NMR (400 MHz, DMSO-d6, TMS): δ 8.57 (s, 1H, 
-CH), 6.34-8.25 (m, 11H, aromatic), 5.18 (s, 2H, -
CH2O), 2.36 (s, 3H, -CH3); 
13C NMR (100MHz, 
DMSO-d6 TMS): δ 160.56 (C-2),112.23 (C-3), 152.50 
(C-4), 120.65 (C-5), 137.50 (C-6), 135.63 (C-7), 
115.87 (C-8), 159.72 (C-9), 117.51 (C-10), 19.40 (C-
12), 191.72 (C-14), 68.98 (C-16), 165.17 (C-
18),79.11 (C-19), 156.18 (C-20), 108.51 (C-21), 
157.21 (C-22), 136.47 (C-24), 126.31 (C-25, C-29), 
129.95 (C-26, C-28), 133.41 (C-27), 21.83 (C-30), 
133.55 (C-31), 130.61 (C-32, C-36), 116.05 (C-33, C-




pyridin-2-yl)oxy) acetate, 7h: Dark yellow solid. 
Yield: 74%, m.p.: 218-220°C, Mol. formula 
C33H28FN3O8. IR (KBr): 3035, 2928 (-CH3), 2224 (-
CN), 1712, 1684 (-C=O), 1641 (C=N), 1165 (aryl-F), 
1515, 1349 cm−1 (-NO2); 
1H NMR (400 MHz, 
DMSO-d6, TMS): δ 8.58 (s, 1H, -CH), 6.37-8.29 (m, 
11H, aromatic), 5.19 (s, 2H, -CH2O), 2.37 (s, 3H, -
CH3), 2.98 (t, 2H, -CH2CH2CH3), 1.67 (m, 2H, -
CH2CH2CH3), 0.97 (t, 2H, -CH2CH2CH3); 
13C NMR 
(100MHz, DMSO-d6 TMS): δ 160.63 (C-2), 112.21 
(C-3), 152.44 (C-4), 120.59 (C-5), 137.52 (C-6), 
135.61 (C-7), 115.83 (C-8), 159.70 (C-9), 117.58 (C-
10), 19.42 (C-12), 191.80 (C-14), 68.91 (C-16), 
165.15 (C-18),79.11 (C-19), 156.16 (C-20), 108.51 
(C-21), 157.24 (C-22), 136.38 (C-24), 127.27 (C-25, 
C-29), 129.39 (C-26, C-28), 143.22 (C-27), 37.41 (C-
30a), 24.12 (C-30b), 13.68 (C-30c),133.61 (C-31), 
130.37 (C-32, C-36), 116.13 (C-33, C-35), 161.61 (C-




yl)oxy) acetate, 7i: Pale Yellow solid. Yield: 70%, 
m.p.: 203-205°C, Mol. formula C30H17BrFN3O7. IR 
(KBr): 3040, 2931 (-CH3), 2230 (-CN), 1714, 1687 (-
C=O), 1642 (C=N), 1161 (aryl-F), 1514, 1351 cm−1 (-
NO2); 
1H NMR (DMSO-d6): δ 8.54 (s, 1H, -CH), 
6.41-8.31 (m, 11H, aromatic), 5.18 (s, 2H, -CH2O), 
2.40 (s, 3H, -CH3); 
13C NMR (100MHz, DMSO-d6, 
TMS): δ 161.56 (C-2), 112.19 (C-3), 152.49 (C-4), 
120.66 (C-5), 137.48 (C-6), 135.69 (C-7), 115.90 (C-
8), 159.69 (C-9), 117.56 (C-10), 19.39 (C-12), 191.68 
(C-14), 68.99 (C-16), 165.20 (C-18), 79.09 (C-19), 
156.20 (C-20), 108.48 (C-21), 157.19 (C-22), 136.44 
(C-24), 126.29 (C-25, C-29), 122.24 (C-26), 126.61 
(C-27), 131.59 (C-28), 133.53 (C-32), 130.69 (C-33, 
C-37), 116.49 (C-34, C-36), 161.47(C-35), 114.48  





yl)oxy) acetate, 7j: Dark Yellow solid. Yield: 66%, 
m.p.: 209-211°C, Mol. formula C36H22FN3O8. IR 
(KBr): 3044, 2926 (-CH3), 2227 (-CN), 1709, 1691 (-
C=O), 1647 (C=N), 1157 (aryl-F), 1519, 1347 cm−1 (-
NO2); 
1H NMR (DMSO-d6): δ 8.53 (s, 1H, -CH), 
6.40-8.01 (m, 16H, aromatic), 5.20 (s, 2H, -CH2O), 
2.39 (s, 3H, -CH3); 
13C NMR (100MHz, DMSO-d6, 
TMS) δ 161.60 (C-2), 112.21 (C-3), 152.54 (C-4), 
120.70 (C-5), 137.98 (C-6), 135.72 (C-7), 115.89 (C-
8), 159.78 (C-9), 117.99 (C-10), 19.47 (C-12), 191.96 
(C-14), 68.77 (C-16), 165.01 (C-18), 79.14 (C-19), 
156.14 (C-20), 108.52 (C-21), 157.14 (C-22), 136.56 
(C-24), 126.24 (C-25, C-29), 156.45 (C-26), 115.61 
(C-27), 131.45 (C-28), 133.69 (C-31), 130.74 (C-32, 
C-36), 116.32 (C-33, C-35), 161.56(C-34), 114.61  




(C-38), 158.09 (C-41), 118.78 (C-42, C-46),  




The broth micro dilution method has been 
employed to determine the MICs of synthesized 
compounds as described in the literature29,30. 
Dimethylsulfoxide (DMSO) was used as diluent to get 
desired concentration of drugs to test upon standard 
bacterial strains. A solvent control of a 1:10 dilution 
of the DMSO was used to dissolve the antimicrobial 
agent being tested. This 1:10 solution is prepared by 
adding 0.1 mL of solvent to 0.9 mL of the appropriate 
diluent. The active candidates found in this primary 
screening were further tested in a second set of 
dilution against all microorganisms. The drugs found 
active in primary screening were similarly diluted to 
obtain 100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM, 
3.125 µM and 1.5625 µM concentrations. The highest 
dilution showing at least 99% inhibition was 
considered the minimum inhibitory concentration 
(MIC). The test mixture should contain 108 organism 
/mL. The control tube containing not any antibiotic 
was instantly subcultured [before inoculation] by 
spreading a loopful evenly over quarter of a plate of 
medium suitable for the growth of test organisms. The 
culture tubes were then incubated for 24 h at 37°C, 
and the growth was observed visually and 
spectrophotometrically. All experiments were done in 
triplicate manner in order to attain the results. After 
that, 10 µg mL−1 suspensions were further inoculated 
on appropriate media and development was noted 
after 24 and 48 h. The lowest concentration 
preventing appearance of turbidity was considered as 
minimum inhibitory concentration (MIC, µg mL−1) 
i.e., the amount of growth from the control tube 
before incubation (which represents the  
original inoculum) was compared. Solvent had  
no influence on strain growth and the result of 
this was greatly affected by the size of inoculum.  
To evaluate the antimicrobial potency of the  
final derivatives, they were screened against  
different strains viz, two gram-positive bacteria 
Staphylococcus aureus (MTCC-96) and 
Streptococcus pyogenes (MTCC-442), two gram-
negative bacteria Escherichia coli (MTCC-443) and 
Pseudomonas aeruginosa (MTCC-1688), and fungi, 
Candida albicans (MTCC-227), Aspergillus niger 
(MTCC-282), and Aspergillus clavatus  
(MTCC-1323), and compared with standard drugs, 
ciprofloxacin and griseofulvin. 
 
Antioxidant assay (DPPH method) 
Reduction of 2,2-diphenyl-1-picrylhydrazyl  
(free radical) is the base of the DPPH antioxidant 
bioassay. It has an odd electron that shows a 
maximum absorption band of 517 nm (deep violet 
colour) in ethanol. The DPPH bioassay is the widely 
used and acceptable method for evaluating the free 
radical scavenging action of the tested compounds. 
Such substances donate a hydrogen atom when mixed 
with the DPPH, thereby introducing its reduced 
congener, diphenylpicrylhydrazine (non-radical)  
with the loss of violet color. In the present study, 
DPPH bioassay was adopted to screen the berberine-
based compounds for their in vitro antioxidant 
profiles. The results of this bioassay investigation 
were introduced in the form of the percentage of 
radical scavenging antioxidant activity (RSA%) of 
each substance. The investigation of the DPPH radical 
scavenging activity was operated according to the 
methodology described by Brand-Williams et al.31 
with some modifications32. A stable free radical, 
DPPH, was allowed to react with test compounds  
in methanol as 20 µg/ mL (100, 10, 1 and 0.1) 
quantities of title compounds were mixed up with 180 
µg/mL of DPPH in methanol. Titled compounds 
donated hydrogen during the mixing thereby 
introduced the reduction of DPPH and hence a change 
in the color was observed from deep violet to light 
yellow at 517 nm after 25 min of reaction in a  
UV–visible spectrophotometer (Perkin-Elmer). The blank 
reading was also performed using the mixture of 
methanol (20 µg/mL) and sample (180 µg/mL of DPPH). 
Ascorbic acid served as a control drug in this assay, and 
its solution was prepared by mixing methanol (20 µg/mL) 
and DPPH radical solution (180 µg/mL). The results of 
this bioassay, RSA% was determined according to33 as 
described in the below equation. 
 
% Scavenging =  




×   
 
Conclusion 
A new series of 4-methyl-6-nitro-2-oxo-2H-
chromen-7-yl 2-((3-cyano-6-(4-fluorophenyl)-4-
(substituted-phenyl)pyridin-2-yl)oxy)acetate has been 
efficiently formulated via coupling 4-methyl-6-nitro-




2-oxo-2H-chromen-7-yl 2-chloroacetate with  
3-cynopyridine derivatives. All the synthesized 
compounds were characterized by spectral techniques. 
Final compounds were evaluated for their in vitro 
antimicrobial activity by broth microdilution method 
and antioxidant activity using DPPH bioassays. The 
presence of chloro and hydoxy group on phenyl ring 
on the chalcone system was essential to exert 
antibacterial, antifungal and antioxidant effect. A 
minimum inhibitory concentration of 7a-j towards 
bacterial and fungal strains was studied and the 
derivatives 7e displayed remarkable potency against 
E. coli with MIC values 50 µg/mL and 7c showed 
equal potency against C. albicans compared to 
standard drugs ciprofloxacin and nystatin 
respectively. It has been observed that the potent 
antibacterial candidate proved to possess significant 
antioxidant activity. The present of hydoxy group on 
phenyl ring plays an important role for the potency in 
above mentioned biological assay. 
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